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TSG TSG TSG
LG IPMN BACKGROUND & AIMS: Intraductal papillary mucinous neoplasms (IPMNs) are regarded as precursors of pancreatic ductal adenocarcinomas (PDAs), but little is known about the mechanism of progression. This makes it challenging to assess cancer risk in patients with IPMNs. We investigated associations of IPMNs with concurrent PDAs by genetic and histologic analyses. METHODS: We obtained 30 pancreatic tissues with concurrent PDAs and IPMNs, and 168 lesions, including incipient foci, were mapped, microdissected, and analyzed for mutations in 18 pancreatic cancer-associated genes and expression of tumor suppressors. RESULTS: We determined the clonal relatedness of lesions, based on driver mutations shared by PDAs and concurrent IPMNs, and classified the lesions into 3 subtypes. Twelve PDAs contained driver mutations shared by all concurrent IPMNs, which we called the sequential subtype. This subset was characterized by less diversity in incipient foci with frequent GNAS mutations. Eleven PDAs contained some driver mutations that were shared with concurrent IPMNs, which we called the branch-off subtype. In this subtype, PDAs and IPMNs had identical KRAS mutations but different GNAS mutations, although the lesions were adjacent. Whole-exome sequencing and methylation analysis of these lesions indicated clonal origin with later divergence. Ten PDAs had driver mutations not found in concurrent IPMNs, called the de novo subtype. Expression profiles of TP53 and SMAD4 increased our ability to differentiate these subtypes compared with sequencing data alone. The branch-off and de novo subtypes had substantial heterogeneity among early clones, such as differences in KRAS mutations. Patients with PDAs of the branch-off subtype had a longer times of diseasefree survival than patients with PDAs of the de novo or the sequential subtypes. CONCLUSIONS: Detailed histologic and genetic analysis of PDAs and concurrent IPMNs identified 3 different pathways by which IPMNs progress to PDAs-we call these the sequential, branch-off, and de novo subtypes. Subtypes might be associated with clinical and pathologic features and be used to select surveillance programs for patients with IPMNs.
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Keywords: Pancreas; Risk Prediction; Tumorigenesis; Progression Model. P ancreatic ductal adenocarcinomas (PDAs) are among the deadliest types of cancers worldwide. A greater understanding of the molecular mechanisms of the development and progression of PDAs may enable us to identify novel ways for prevention, early detection, and effective therapy. It is hypothesized, or indeed seems to be established, that PDAs are associated with 2 precursor types that are morphologically distinct from each other: pancreatic intraepithelial neoplasias (PanINs) and intraductal papillary mucinous neoplasms (IPMNs). 1 PanINs are microscopic intraepithelial lesions that comprise tall columnar cells with variable atypia, whereas IPMNs are grossly visible intraductal tumors that show well-developed papillae. 2 Moreover, IPMNs are heterogeneous tumors with varying histologic grades (ie, low grade [ LG] and high grade [HG] ) and diverse epithelial types (ie, gastric, intestinal, pancreatobiliary, and oncocytic). 3 Depending on the epithelial type, IPMNs have variable prognosis, including subsets with unequivocal potential to progression into invasive carcinomas. 4 PanINs may progress to invasive carcinomas in a stepwise and straightforward fashion, which is established as the progression model for pancreatic cancer. 5 Although this PanIN progression model may be proven by molecular studies of human tissue samples and genetically engineered mouse models, 6, 7 the mechanism of IPMN progression into invasive cancer remains to be clarified. An invasive carcinoma may arise in the pancreas with IPMN in either an associated/derived way or a distinct/concomitant way, 1 and the associated carcinomas may have a poorer prognosis than the concomitant carcinomas. 8 However, little evidence for this model of IPMN progression, either associated or concomitant, has been shown so far, 9 and thus, whether this model is appropriate for interpreting IPMN progression is unknown.
Recent large-scale molecular analyses uncovered a GNAS mutation as a distinct molecular alteration for IPMN. Somatic mutations in GNAS seem to be specific for IPMNs. Therefore, a small fraction of PDAs and the precursors harboring GNAS mutations or amplifications may be IPMNassociated cancers and incipient IPMNs, respectively. [10] [11] [12] [13] Although the early acquisition of KRAS mutation is likely to be essential for the development of PanINs, 13 mutations in GNAS appear to play a pivotal role in the development of IPMNs, which has been proven by a number of molecular studies of human tissues and genetically engineered mouse models. 11, 14, 15 It is suggested that molecular profiling of KRAS and GNAS is helpful for understanding whether invasive cancers in the pancreas with IPMN are either associated or concomitant; however, to further elucidate the mechanisms of IPMN progression into invasive carcinomas, a detailed molecular analysis of precisely evaluated microdissected tissues from human clinical samples of IPMNs and invasive cancers may be necessary. In addition, early lesions in the background of normal-appearing pancreas with IPMNs may provide a clue to understanding the basis of the field carcinogenesis, ie, the occurrence of multifocal, or potentially disseminated, epithelial tumors being preceded by and associated with widespread changes in the organ fields, which may represent a pattern of progression. 1, 16 This study aimed to identify molecular paths marked by genetic mutations and expressions between IPMNs and invasive carcinomas in resected pancreata, which would uncover the mechanism of progression of IPMNs and its clinical relevance. Thus, we sought to trace the genetic evolution based on exhaustive mapping of multicentric/ synchronous lesions, including incipient tumors, in whole resected specimens of pancreata with IPMN and invasive carcinoma. Using this approach allowed us to identify novel molecular mechanisms of IPMN progression into invasive carcinoma, which may serve to establish better
WHAT YOU NEED TO KNOW
BACKGROUND AND CONTEXT
The mechanisms by which intraductal papillary mucinous neoplasms (IPMNs) progress to pancreatic ductal adenocarcinomas (PDAs) are not clear.
NEW FINDINGS
Comparing patterns of mutations between PDAs and concurrent IPMNs found IPMNs to progress via sequential, branch-off, and de novo pathways.
LIMITATIONS
Targeted sequencing for limited number of genes using formalin-fixed and paraffine-embedded tissue samples.
IMPACT
Information on the pathways by which IPMNs progress to
PDAs could be used in designing surveillance program for patients with IPMN.
surveillance of individuals at high risk for IPMN progression into PDA.
Methods
Study Design and Participants
This study was approved by the institutional review board of Teine-Keijinkai Hospital (RIN2014-49 and TA2018-030) and Tokushukai Group Ethical Committee on Human Research (TGE00369-012). Written informed consent was obtained from patients before enrolment. All authors had access to the study data and reviewed and approved the final manuscript.
According to the database of the Department of Pathology at Teine-Keijinkai Hospital and Sapporo Higashi Tokushukai Hospital, 284 Japanese patients underwent pancreatectomy for invasive pancreatic cancers from January 2011 through June 2016, and 39 of these patients had concurrent IPMN and PDA (13.7%). Among them, 7 mucinous adenocarcinomas and 2 tubular adenocarcinomas were excluded, because these invasive foci were too small for subsequent sequencing analyses. Therefore, a total of 30 patients harboring concurrent IPMN and PDA, namely, patients with IPMN-related PDA, were enrolled in this study ( Supplementary Table 1 ). Clinical information was collected on patient age, sex, PDA diagnostic clues, familial pancreatic cancer relatives, other cancer histories, imaging study results, and prognosis. Resected pancreata were fixed in 10% buffered formalin, and an entire specimen was sliced in 5-mm-thick sections, which resulted in 17-72 (average, 33.8 ± 12.4) formalin-fixed paraffin-embedded (FFPE) blocks for each specimen.
Histologic Evaluation
Whole sections of the resected specimens, including nontumoral areas, were reviewed, and precise navigation maps showing a distribution of each invasive cancer and IPMN were drawn (Supplementary Figure 1 ). In addition to the macroscopic lesions, we also performed a thorough investigation of microscopic neoplastic lesions (MNLs) in the rest of pancreas. 17, 18 All sections were examined by 4 physicians, including 2 pathologists (Y. Omori, MT, HK, and YM), and pathologic assessment of epithelial types (gastric, pancreatobiliary, intestinal, or oncocytic) and dysplastic grades (LG or HG) of IPMNs was performed as described previously. 19, 20 We histologically defined IPMN-derived PDA as PDA exhibiting continuity with HG IPMN (Supplementary Figure 1A ) and concomitant PDA as PDA without continuity with IPMN or that adjoining LG IPMN (Supplementary Figure 1B) , based on the previously described criteria. 8, 21 Besides the pathologic assessment, the clinical course and images over time were also referred to interpret the association between IPMN and concurrently developed PDA in this study. IPMN that was notable or was nearest to a PDA was designated as a co-existing IPMN in this study. Based on the histologic maps, 168 lesions (3-13 samples, with an average of 5.6 samples per patient) of invasive carcinomas, IPMNs, and MNLs were selected for molecular analysis. We evaluated 10 HG IPMN patients without invasive cancer who were sex-, age-, and epithelial type-matched with 30 patients with IPMN-related PDA to elucidate the heterogeneity of the IPMN progression (Supplementary Tables 1 and 2 , cases 31-40).
Conceptual Definitions of IPMN Progression Paths
We conceptually hypothesized 3 distinct progressions of IPMN into PDA, namely, sequential, branch-off, and de novo subtypes, which were assumed by clonal relatedness determined by shared mutations between PDA and coexisting IPMN. In the sequential subtype, PDA develops directly or sequentially from IPMN, and IPMN and PDA share driver mutations. In the de novo subtype, PDA develops independently from IPMN, and IPMN and PDA have distinct driver mutations. In the branch-off subtype, PDA and IPMN develop divergently in a forked fashion from an ancestral clone, and IPMN and PDA share initiating driver mutations but become distinct in having different promotive mutations.
Molecular Analysis
The immunohistochemical staining of mucins (MUCs) and CDX2 were used to assess the epithelial type of IPMNs. 1 In addition, the overexpression and complete loss of expression of TP53; loss of expression and weak expression, suggesting haploinsufficiency, of SMAD4; loss of expression and overexpression of p16; loss of RNF43 expression; and nuclear accumulation of b-catenin were assessed as aberrant protein expressions (Supplementary Figure 2 ). 22 Antibodies used for immunohistochemistry are listed in the Supplementary Methods.
For multiregion sequencing, 178 neoplastic lesions containing invasive carcinomas, IPMNs, and MNLs were dissected from FFPE sections by means of laser capture microdissection (LMD6500, Leica Microsystems) or manual microdissection on a microscope (Eclipse 80i, Nikon) with a fine sterile needle, and 5,000 or more neoplastic cells were collected per sample. Neoplastic cellularity in each sample was estimated in a 10% order (20%-100%) for assessing variant alleles' frequency in the sequencing data. Genomic DNA was then purified and isolated from paired tumors and normal tissue samples using the GeneRead DNA FFPE Kit (Qiagen), according to the manufacturer's instructions.
Mutation profiles of tumors were determined primarily by targeted amplicon sequencing. 17 In this study, we designed an PDA/IPMN-related gene panel (Ion AmpliSeq Custom DNA Panel) using Ion AmpliSeq Designer 3.6 to analyze the DNA sequences (coding DNA sequences ±25 base pairs of intronic flanking regions) of 18 genes: 4 classic PDA-related driver genes, KRAS, TP53, SMAD4, and CDKN2A; GNAS mutations as a hallmark molecular alteration occurring in a majority of IPMNs; genes related to core signaling pathways in PDA, such as KRAS-(BRAF, PIK3CA, and MAP2K4), transforming growth factor (TGF)-b-(TGFBR1, TGFBR2), and WNT-signaling (RNF43, CTNNB1); and other previously reported genes recurrently mutated in PDA and IPMN (STK11, ARID1A, KDM6A, SF3B1, RBM10, and IDH1) 12, 23, 24 (Supplementary Table 3 ). The Supplementary Methods provide details of the custom-made panel, methods of mutation calling, and the quality and threshold of the sequencing data. When DNAs were too heavily fragmented for targeted amplicon sequencing, the mutations in KRAS (codons 12 and 13) and GNAS (codon 201) were analyzed by digital polymerase chain reaction (PCR) (QX200 Droplet Digital PCR System, Bio-Rad). For further details, see the Supplementary Methods and Supplementary Tables 4-6 . We successfully obtained genotypes using digital PCR from 11 DNA samples in which library preparation during sequencing failed in the 178 lesions (6.2%). Given the minimal amount of DNA, tumor suppressors with a wide range of variants rather than specific hot spots were not analyzed by the digital PCR assay. In the Supplementary Methods, we describe techniques for wholeexome sequencing and DNA methylation profiling.
Statistical Analysis
The disease-free survival was defined as the time from the date of surgery to the time of recurrence and emergence of new neoplastic lesions requiring intervention or the date of the last follow-up. We constructed Kaplan-Meier curves and Cox proportional-hazard regression models, and we calculated hazard ratios with 95% confidence intervals of disease-free and overall survival.
Concordance of the molecular profiles of the coexisting IPMN and the related PDA were summarized according to the mutation profiles of the 18 PDA/IPMN-related genes generated by the targeted amplicon sequencing. For TP53, SMAD4, p16, RNF43, and b-catenin, the protein expression levels also converged. To visualize the profiles for each IPMN-PDA pair, we used the following categories: A, no mutation or aberrant protein expression was identified in both the co-existing IPMN and related PDA; B, mutation or aberrant protein expression was found only in the coexisting IPMN; C, mutation or aberrant protein expression was found only in the PDA; D, mutation or aberrant protein expression found in the coexisting IPMN was identical to that in related PDA; and E, mutation or aberrant protein expression found in the coexisting IPMN was distinct from that in the related PDA.
The significance threshold was set at P < .05 for all statistical tests unless otherwise stated. The relevance of any association was assessed using Fisher's exact test for categorical data, and continuous data were compared between groups using the Mann-Whitney U test. Statistical or bioinformatics analyses were performed using R, version 3.3.2 (The R Foundation).
Data Availability
Exome sequencing data have been deposited in the DNA Data Bank of Japan (DDBJ) Sequence Read Archive (accession number: JGAS00000000152). In addition, the associated DNA methylation microarray data sets have been deposited into the Gene Expression Omnibus (accession number: GSE114163).
Results
Clinicopathologic Characteristics of Patients With IPMN-Related PDA
Among 284 consecutive patients who underwent pancreatectomy for PDA, 17 (6.0%) IPMN-derived PDAs and 22 (7.7%) concomitant PDAs were found. Seven mucinous adenocarcinomas that originated from intestinal-type IPMNs and 2 concomitant PDAs were excluded because they had few invasive foci. Among 30 patients with IPMNrelated PDA, 6 had recurrent pancreatic cancer in the remnant pancreas and underwent remnant pancreatectomy, that is, IPMN-derived mucinous adenocarcinomas after pancreatectomy for IPMN-derived mucinous adenocarcinomas in 2 patients (cases 5 and 6, for details refer Supplementary Figures 3 and 4 ), independent tubular adenocarcinomas after pancreatectomy for HG IPMN in 2 patients (cases 20 and 27), concomitant PDA after pancreatectomy for concomitant PDA in 1 patient (case 21), and intrapancreatic metastases after pancreatectomy for concomitant PDA in 1 patient (case 23). In addition, 3 of the 6 recurrent PDAs were considered metachronous secondary invasive cancer based on the histologic relation to a noninvasive compartment of IPMN (cases 5, 6, and 21). Finally, 12 IPMN-derived PDAs and 21 concomitant PDAs were subject to the molecular analysis ( Figure 1A and Supplementary Table 1 ). There was a difference in epithelial types of coexisting IPMNs between the 2 cohorts; concomitant PDAs were more frequently related to gastric-type IPMNs than IPMN-derived PDAs were.
Novel Subtypes of IPMN-Related PDAs Defined by Molecular Alterations
Alterations of the 18 PDA/IPMN-related genes and expression profiles of tumor suppressor molecules were plotted in conjunction with distances between invasive cancers and IPMNs and morphologic features ( Supplementary  Figures 3 and 4 and Supplementary Table 2 ). There was a clear difference in the frequency of mutations in KRAS and GNAS between IPMN-derived PDAs and concomitant PDAs (Supplementary Table 1 ). The TP53 abnormality was more frequently observed in concomitant PDAs than IPMN-derived PDAs (71% vs 33%, P ¼ .0656). We re-evaluated the morphology-defined progression model, that is, derived/ associated vs concomitant/distinct, based on the molecular profiles. For IPMN-derived PDAs, sequential progression was fully confirmed by the molecular signatures as the mutations in KRAS and GNAS originally assigned in IPMN were succeeded in the invasive compartment ( Figures 1 and 2A and Supplementary Table 7 ). Furthermore, TP53, SMAD4, and CDKN2A/p16 alterations were succeeded and accumulated more intensely in such PDAs compared with the coexisting IPMNs, which indicated progression with an accumulation of the molecular abnormalities (Table 1 ). Hence, we designated this category as a sequential molecular subtype. Curiously, tumor subclones with abnormalities in RNF43 and CTNNB1/ b-catenin were not likely to be selected during the tumor progression in this subtype (Supplementary Table 7 and Supplementary Figure 5 ).
KRAS mutations were detected in 20 of the 21 (95.2%) concomitant PDAs and 38 of 39 (97.4%) IPMNs existing simultaneously with the PDA elsewhere in the same specimen. The PDAs harboring KRAS mutations identical to those in IPMNs were at a significantly closer distance to the IPMNs (n ¼ 16; distance range, 0-35 mm; median, 5 mm) compared with PDAs with KRAS mutations different from those in IPMNs (n ¼ 23; distance range, 0-75 mm; median, 15 mm, P ¼ .0397) ( Figure 1B and Supplementary Figure 6 ). Mutations in GNAS were detected in 14 of the 20 (70%) IPMNs closely coexisting with PDAs and 29 of all 39 (74%) IPMNs identified in the specimens, including those apart from PDAs but not in the concomitant PDAs themselves. This suggests independent carcinogenesis rather than a sequential progression from the IPMNs (Supplementary Figure 3 ). We classified the concomitant PDAs into 2 subtypes, de novo and branch-off, according to the concordance of KRAS mutation status with the coexisting IPMN (Table 1) . Obviously, the de novo subtype PDAs were likely to develop from founder clones independent of the IPMNs because of their distinct mutant KRAS variants (10/21 PDAs, 50%) ( Figures 1C and 2B) . Conversely, the branch-off subtype PDAs seemed to diverge from the same ancestor comprising coexisting IPMNs because those PDAs and IPMNs shared identical KRAS mutations with different profiles of other molecules. The latter subset may be composed of various subclones that branched from the founder clones at distinct temporal ordering. Alternatively, the early subclone may be disseminated via the pancreatic duct or bloodstream. 25, 26 Indeed, all 3 patients (cases 12, 13, and 18) with contiguous neoplastic lesions via the main pancreatic duct between PDAs and IPMNs had identical KRAS mutations ( Supplementary Figure 3) .
A Unique Tumor Evolution Path in the Branch-Off Subtype
In both the branch-off and the sequential subtypes, PDAs and coexisting IPMNs share identical KRAS mutations at an equivalent allele frequency ( Figure 1A and Supplementary  Figure 7 ). We performed detailed comparison of mutation signatures to evaluate how the 2 subtypes differed from each other. There was a discordance in GNAS mutation status between the coexisting IPMN and PDA in 6 of the 11 tumors categorized in the branch-off subtype (54.5%) ( Figure 1C , Table 1 and Supplementary Figure 3 ). On the other hand, all tumors in the sequential subtype shared GNAS signatures between coexisting IPMNs and PDAs ( Figure 1C ).
Next, we performed whole-exome sequencing in selected tumor samples of the branch-off subtype (cases 13, 18, and 25) to further strengthen the accuracy of the KRAS mutation as a determinant of shared ancestry. Besides the KRAS mutation as a tracer in this subset, recurrent sequence variations were identified in the coding region of putative drivers of BCLAF1 and in noncoding regulatory regions of several cancer-associated genes, including NBPF1 and USP6, 12, 27 among lesions assumed to branched off from a common founder clone ( Figure 2C, Supplementary Figure 8 , and Supplementary Table 9 ). Such traceable mutations were more often observed among branch-off IPMN-PDA pairs sharing the KRAS mutations than the interpatient heterogeneity 28 (Supplementary Figure 8 ). Furthermore, additional DNA methylation profiling among multiple tumor compartments in the branch-off subtype showed a close relationship during clonal expansion, especially in the CpG island ( Figure 2C and Supplementary Figure 9 ).
To gain deeper insight into the differences in molecular profiles among the subtypes, immunohistochemistry data were integrated into the mutation profiles. Besides the discordance in the GNAS mutation, expression profiles of TP53 and SMAD4 offered a better resolution for differentiating the sequential subtype PDAs from the branch-off subtype PDAs ( Figure 1C and Supplementary Figure 10) .
To determine the prognostic significance of the progression subtypes of IPMN, disease-free and overall survivals were compared among the subtypes. We found that patients with the branch-off subtype PDA showed significantly longer disease-free survival than those with the de novo subtype PDA (hazard ratio, 4.056, P ¼ .04376), even in this small cohort, and their mean survival time was the longest among the 3 molecular subtypes (Figure 3 ). There was no significant difference in overall survival among the 3 molecular subtypes.
Molecular Subtypes and the Genetic Diversity of Early Synchronous Early Clones
Next, we evaluated synchronous early clones distributed in the entire pancreas by their genetic diversity. MNLs, either PanINs or incipient IPMNs, 18 in the background of normal-appearing pancreas, were found significantly more frequently in the branch-off (P ¼ .0232) and the de novo subtypes (P ¼ .0147) than in the sequential subtype ( Figure 4A ). KRAS mutations were found in the majority of MNLs regardless of the molecular subtypes, and their variant allele frequencies were equivalent to LG IPMNs ( Figure 4B and Supplementary Figure 7) . Notably, the KRAS mutations of the neoplastic lesions in each pancreas were more varied in the branch-off subtype (P ¼ .0046) and the de novo subtype (P ¼ .0018) than in the sequential subtype ( Figure 4C and D) , which suggests that the branch-off and the de novo subtypes are associated with substantial heterogeneity in founder clones. GNAS mutations were more frequent in MNLs in the sequential subtype than in MNLs in the branch-off (P ¼ .015) or de novo subtype (P ¼ .036) ( Figure 4B ). Besides the KRAS and GNAS mutations, a considerable fraction (20%-30%) of the incipient lesions was marked by tumor suppressor pathway alterations ( Figure 4E , Supplementary Table 2 , and Supplementary Figure 4B ; case 21). The distribution of mutations in tumor suppressor genes in the MNLs was not statistically associated with either the molecular subtypes or mutations in KRAS or GNAS. 
Accumulation of Aberrant Molecular Pathways in IPMN-Related PDAs
Finally, molecular signatures of IPMN-related PDAs were summarized according to the accumulation of aberrant molecular pathways. Consistent with genomic analyses of conventional PDAs elsewhere, 29 the PDAs concurrent with IPMNs analyzed in this study seemed to pursue the classic PDA paths: with activating mutations of KRAS in 84.8%, deleterious mutations of TP53 in 42.4%, TGF-b signaling (SMAD4, TGFBR1, and TGFBR2) in 34.3%, and CDKN2A in 9.1% ( Supplementary Figure 11 and Supplementary  Table 8 ). Twenty-six of 33 IPMN-related PDAs (78.8%) harbored at least 1 mutation in the major tumor suppressors ( Supplementary Figure 11) . Then, we evaluated the correlation between mutation and immunohistochemical profiles, focusing on TP53, SMAD4, CDKN2A/p16, CTNNB1/ b-catenin, and RNF43 ( Supplementary Figure 12 and Supplementary Table 10 ). The TP53 mutations exhibit strong concordance with protein expression abnormalities irrespective of the tumor grade (ie, IPMN vs related PDA). Furthermore, the SMAD4, CTNNB1, and RNF43 mutations observed in IPMN exhibited a good correlation with the aberrant protein expression; however, the concordance was not found in related PDA.
TP53 appeared to be a key gatekeeper during the progression of IPMN to invasive cancer, whereas Wnt abnormality (CTNNB1/b-catenin and RNF43) was more frequently observed in IPMN without PDA ( Figure 5A ). Furthermore, higher cellular rate with abnormal SMAD4 expression in the sequential subtype was observed relative to the HG IPMN without PDA, although there was no significant difference in abnormal TGF-b module accumulation between the 2 groups (Supplementary Table 2 and Figure 5A ). A larger number of abnormal modules were accumulated in PDAs of the branch-off and de novo subtypes than in those of the sequential subtype, but this was not statistically significant (P ¼ .123) ( Figure 5A ). Focusing on associations with GNAS mutations more specifically, accumulations of aberrations in molecular paths determined by the aberrant protein expression or deleterious mutation in KRAS, TP53, CDKN2A, TGF-b, and Wnt signaling in IPMNrelated PDAs were not as obvious in GNAS-mutant PDAs than GNAS-wild-type PDAs (1.75 vs 2.84, P ¼ .00384). Additionally, 6 PDAs with at least a partial component of mucinous adenocarcinoma, 5 of which were GNAS mutants and 1 of which was a GNAS-wild-type PDA, had fewer aberrant core modules than those with tubular adenocarcinomas (1.33 vs 2.85, P ¼ .00015, Figure 1C and Supplementary Table 2 ).
Discussion
Pancreatic cysts, including IPMNs, are associated with a 19.6-22.5-fold increased risk of PDA development. 30, 31 Given the large population of individuals with pancreatic cysts of equivocal malignant potential and the dilemma of missing the opportunity to diagnose concurrent PDAs at earlier stages during follow-up, risk stratification based on precise clinical and biological data is needed. 32, 33 Here, we propose a revised progression model for IPMN by classifying its carcinogenic pathways into 3 molecular subtypes by exhaustive genetic mapping using entire pancreatectomy specimens of patients with IPMN-related cancers ( Figure 5B ). This model provides significant findings for the construction of a novel risk-prediction algorithm regarding molecular diversity for early detection of carcinogenesis in the surveillance of IPMN patients.
Earlier studies generated considerable information regarding KRAS and GNAS mutations in clinically notable IPMNs and related cancers. 10, 11, 34, 35 Initially, the GNAS mutation was thought to be associated with a particular epithelial type, such as intestinal-type IPMN or mucinous (colloid-type) carcinoma; 35 however, the evidence obtained in human specimens, as well as in genetically engineered mouse models, did not show that GNAS directly regulates such phenotypes. 15 Thus, we sought to ascertain whether the spatiotemporal landscape of the 2 driver mutations may govern the field aberrations in the pancreas, suggesting a new paradigm in which the fate of patients with clinically noticeable IPMNs could be accurately predicted. To date, efforts to trace the molecular signatures extensively within the entire pancreas covering microscopic satellite lesions in the background of normal-appearing pancreas have not yielded any results. In this study, we defined distinct progression paths based on the patterns of combinations of the KRAS and GNAS mutations in conjunction with the abnormality of SMAD4 and TP53 across coexisting IPMNs and related PDAs. Furthermore, we also provided insights into the clonal heterogeneity of multicentric/synchronous incipient lesions. 28, 36 Clinical parameters provided by the current guidelines are mostly for the prediction and grading of clinically noticeable IPMNs; 21 therefore, such a strategy covers only the sequential subtype, which comprises one-third of IPMNrelated PDAs. In this molecular subtype, the invasive compartment completely inherits the KRAS and GNAS signature from the IPMN per se. Molecular tracing proved that sequential IPMNs indeed progress to invasive carcinomas with an accumulation of abnormalities in CDKN2A/ p16, SMAD4, and TP53 in a stepwise and straightforward fashion. However, it should be noted that subclones with abnormalities in CTNNB1/b-catenin and RNF43 may have less ability for clonal progression. 37 Another two-thirds of the PDAs that concomitantly developed in IPMN patients appeared to be a result of progression via evolutionally distinct pathways, specifically, the branch-off pathway or the de novo pathway. A significant number of incipient lesions and their clonal diversity, attributed to varying KRAS mutations, were characteristic features for the pathways, and such a significant heterogeneity in the synchronous tumorigenesis could be associated with genetic susceptibility and could be a potential factor for estimating candidates at high risk of developing concomitant PDAs. The main difference between the 2 molecular subtypes is whether the concurrent PDA arose from a common founder clone with a coexisting IPMN or from an entirely independent clone from the IPMN. The de novo subtype identified in this study may be consistent with the finding of Felsenstein et al. 38 that indicated the independent development of PDA from concurrent IPMN. Moreover, the branch-off subtype could correspond to some cases in their study showing partially shared mutations between IPMNs and PDAs adjacent each other ( Figure 1A and B and Supplementary Figure 6 ). Although PDA-related modules were highly enriched in PDAs in both subtypes of pathway ( Figure 5A) , the branch-off subtype PDAs represented better disease-free survival (Figure 3) , implying that such a tumor subset may be less capable of rapid progression that might be attributed to a unique molecular signature.
The mode of pancreatic tumorigenesis may be fated by early clones harboring the KRAS and GNAS mutations long before the emergence of PDA. The high frequency (>90%) of KRAS mutations found in the majority of MNLs, regardless of the progression subtypes ( Figure 4B and Supplementary  Figure 7) , suggests that the KRAS alteration is the earliest event involved in PDA development related to IPMNs. 13 Of note, the branch-off and de novo subtypes are associated with the substantial heterogeneity in early clones marked by various KRAS mutations. Despite the frequent presence of coexisting IPMNs with oncogenic GNAS even in the branchoff (6/11 patients) and de novo (8/10 patients) subtypes, the frequency of the GNAS mutation in MNLs in pancreata of patients with these subtypes was considerably smaller than in those with the sequential subtype ( Figure 4B) . Thus, the high burden of GNAS-mutant clones and less divergence in KRAS variants elsewhere in the pancreas could be predictive factors for the sequential subtype; conversely, low abundance of GNAS-mutant clones with diverse KRAS variants could indicate the fate of the de novo and branch-off subtypes. We recently showed that oncogenic GNAS induces unique metabolic reprogramming during pancreatic tumorigenesis. 39 Despite specific oncogenic function and tumor maintenance roles, GNAS-driven circuitry in cell signals may result in lower clonal expansion with less invasiveness relative to the KRAS-mutant precursors in the context of pancreatic neoplasia. To assess the mutations' burden and diversity, endoscopic ultrasonographically guided fine needle aspiration may be less informative because it can provide only locoregional information, unless multiple biopsies are performed. 40 Current liquid biopsy technology, sequencing DNA from blood, pancreatic juice, and duodenal fluids, may offer minimally invasive procedures allowing genotyping across the whole pancreas. 41, 42 A major limitation of the present investigation was the analysis of only 18 molecules in a small sample size required to draw a molecular landscape. There were considerable discrepancies between mutations in SMAD4, CTNNB1, and RNF43 and their expression patterns ( Supplementary Table 10 ). Possible reasons for the discordance may be the presence of missense mutations and haploinsufficiency, which may cause sustained expression. Inversely, some variants causing loss of expression may be missed by our custom-made panel. Additionally, we could not determine copy number alterations; therefore, associations between genetic and expression phenotypes remain to be determined for these molecules. However, given the limited information of the effect of RNF43 variants on protein expression and Wnt activation, 43 our results on targeted sequencing of RNF43 covering the whole coding region will contribute to the accumulation of data regarding deleterious variants. IPMN-related PDAs (with a large compartment of invasion) accounted for only 10% of curatively resected PDAs in our institutions, and others were often diagnosed at unresectable stages, even during routine follow-up of preceding IPMNs. Although larger cohorts of over 100 patients elsewhere have identified a major landscape of PDA-associated genetic signatures, 24, 29 the majority of these investigations involve conventional PDAs that may differ from the PDAs specifically observed in IPMN patients. Given the limited access to whole pancreatectomy specimens of IPMN-related PDAs, analyses of the 30 patients in the current study are invaluable. Thus, this investigation provides substantial evidence showing molecular paths for clonal evolutions that explain associations between a PDA and coexisting IPMN, which, to our knowledge, has not been precisely addressed in earlier studies.
Another concern expressed may be the concept of the newly proposed branch-off subtype. The subtype provides a concept of forking during progression that results in 2 distinct tumor phenotypes from the common founder clone, explaining the tumorigenic process of closely localized PDA and coexisting IPMN. The matched KRAS mutation between invasive carcinoma and a coexisting IPMN may be coincident, and such an event is statistically probable, regardless of the distance between tumor compartments. However, we are convinced that the branch-off subtype PDA provides a distinct progression model regarding outcomes after resection, distance from coexisting IPMN, and the substantial heterogeneity in KRAS mutation of associated synchronous clones. The similarity in the methylation profile, together with traceable and potentially deleterious mutations identified by exome sequencing (eg, BCLAF1) also support our progression model of IPMN ( Figure 2C and Supplementary Figure 8 ). Nevertheless, more comprehensive analysis such as whole-genome sequencing and transcriptome profiling, ultimately at the single-cell level, may provide additional robust evidence elucidating the mechanism of molecular progressions of IPMN toward PDA.
One of the major debates in the clinical community is how to define the risk stratification methodology for pancreatic cancer, 1 and a field defect associated with IPMN provides a relevant human model of the disease. Because IPMN comprises multicentric/synchronous lesions rather than a single locoregional disease, quantitative and qualitative evaluations of KRAS and GNAS mutations, together with abnormalities in the TGF-b pathway and G1/S checkpoint machinery, may give information for the surveillance of the whole pancreas in patients with IPMN. Our data may promote further revision of the current algorithm for surveillance of IPMN and warrant future clinical studies to evaluate the molecular subtypes of PDAs related to IPMN, which can potentially overcome the dilemma regarding the management of these patients.
Targeted Amplicon Sequencing
We designed an PDA/IPMN-related gene panel (Ion AmpliSeq Custom DNA Panel) using Ion AmpliSeq Designer 3.6 to analyze the DNA sequences. The custom panel comprised 220 amplicons divided into 2 primer pools, for a total of 17.8 kilobases of DNA and covered 99.59% of the regions of interest. Approximately 10-60 ng of genomic DNA was amplified using this panel, and a sequencing library was prepared. Sequencing and data analyses were performed using the Ion PGM System (Thermo Fisher Scientific) as previously described. 3 Sequenced reads were demultiplexed, quality-filtered, and aligned to the human reference genome (GRCh37) with the Torrent Suite software package, version 5.0.4 (Thermo Fisher Scientific). The mapping module, named the Torrent Mapping Alignment Program, is a sequence alignment software program optimized specifically for Ion Torrent data, including several mapping algorithms, each with its appropriate application. Mapping was operated with the default parameter values.
Variants were identified using the Variant Caller plugin, version 5.0.4.0 (Thermo Fisher Scientific) included in Torrent Suite Package, optimized to exploit the underlying flow signal information. Variant calling analysis was operated using somatic variant calling mode optimized to detect low-frequency variants, setting the parameters as follows: minimum allele frequency, 0.02; minimum coverage, 100. To identify somatic mutations, independent genotyping of the tumor and normal samples (duodenum or spleen) were subtracted; variants found in the normal samples were excluded from the molecular profiling. We excluded putative false-negative variants by evaluating the Phredscaled variation call quality calculated by this plugin and by manually confirming the alignment by Integrative Genomics Viewer software, version 2.3.59 (http://software. broadinstitute.org/software/igv/).
For variants, consisting of novel exonic nonsynonymous and frameshift variants, as well as intronic splicing variants, the COSMIC (http://cancer.sanger.ac.uk/cosmic) and Clin-Var databases (https://www.ncbi.nlm.nih.gov/clinvar/) were consulted for classification as either pathogenic or variant of unknown significance. Prediction of the functional effects of amino acid substitutions and indels were performed using PROVEAN (http://provean.jcvi.org/index.php) and/or SIFT (http://sift.jcvi.org).
Mutation Detection by Digital PCR
Mutant KRAS variants (codons 12 and 13) or mutant GNAS variants (codon 201) were analyzed using a QX200 Droplet Digital PCR System (Bio-Rad), as described previously. 4 Custom probes and primers were designed for 8 major mutations in KRAS codons 12 and 13 or GNAS codon 201; sequences are presented in Supplementary Table 4 . The reaction mixture was prepared as described in Supplementary Table 5 . Purified genomic DNA was partitioned into approximately 22,000 droplets per sample by mixing with 70 mL Droplet Generation Oil in a QX200 droplet generator (Bio-Rad). Droplets were then subjected to thermal cycling, as described in Supplementary Table 6 . Samples were transferred to a QX200 droplet reader (Bio-Rad) for fluorescence measurement of 6-fluorescein amidite and hexachlorofluorescein probes. Droplets were scored as positive or negative based on their fluorescence intensity, which was determined by the gating threshold defined using positive and negative controls. Finally, absolute copy number input in the reaction and the ratio of the mutated fragment were calculated by QuantaSoft, version 1.7 (Bio-Rad) software based on the Poisson distribution.
Whole-Exome Sequencing
Whole-exome capture was performed with SureSelectXT Human All Exon, version 6 (Agilent Technologies) for samples from cases 13, 18, and 25 (all categorized as the branch-off subtype) (see Figure 1 and Supplementary  Table 2 ). The captured targets were subjected to massive sequencing using NovaSeq 6000 (Illumina) with the pairend 150-base pair read option. Information of reading depth is provided in Supplementary Table 9A .
The sequencing reads were aligned to the National Center for Biotechnology Information Human Reference Genome Build 37 hg19 with BWA, version 0.7.12, with default parameters (http://bio-bwa.sourceforge.net/). PCR duplicate reads were removed with Picard, version 1.130 (http://www.picard.sourceforge.net). Mutation calling was performed using The Genome Analysis Toolkit (GATK version 3.8-1-0) MuTect2 algorithm with default parameters (https://software.broadinstitute.org/gatk/). Then, variations were annotated with SnpEff, version 4.3t (http:// snpeff.sourceforge.net/SnpEff.html).
The variants with the following criteria were annotated as somatic mutations;
Read (or sequence) depths 10 in both the tumor sample and paired normal sample Variant reads in tumors 4
Variant allele frequencies in tumor samples 10%
Eliminate variants located in the intergenic region.
Eliminate variants over 10% identified in the paired normal sample
The multiregional mutation profile obtained for each case is visualized as a heat map whose intensities represent VAFs. From the mutation profiles, maximum parsimony trees were constructed using the maximum likelihood algorithm in the MEGA7 package (http://evolgen.biol.se.tmu. ac.jp/MEGA/).
DNA Methylation Profiling
Genomic DNA from the case 18 was bisulfite-treated using the EZ-96 DNA Methylation Kit (Zymo Research Corporation), and genome-wide DNA methylation was profiled with the Illumina Infinium MethylationEPIC BeadChip kits (Illumina). The microarray images were obtained using the Illumina iScan scanner. Preprocessing and normalization involved steps of background correction and dye bias equalization, filtering, and Beta MIxture Quantile normalization. 5 A methylation level of each probe was then obtained as a b value. In analyses of methylation variance, CpG island was based on probe information of the MethylationEPIC BeadChip. Array data export processing and analysis were performed using Illumina GenomeStudio, version 2011.1 (Methylation Module, version 1.9.0) and R 3.0.2 (http:// www.r-project.org). Clustering was performed using Cluster 3.0 software 6 , and the result was visualized by Java Tree View (http://jtreeview.sourceforge.net). Furthermore, CpG islands (161,167 probes) were extracted from total probes (858,657 probes) to compare their similarities by scatterplots and to calculate the correlation coefficient and 95% confidence interval of each pair with R 3.1.0 software.
